Overview
NICE is unable to make a recommendation about the use in the NHS of bosutinib (Bosulif) for untreated chronic myeloid leukaemia. This is because Pfizer did not provide an evidence submission.
Last reviewed: 17 April 2019
Next review: We will review this decision if the company decides to make a submission.